Canada markets open in 1 hour 10 minutes

AIM ImmunoTech Inc. (AIM)

NYSE American - NYSE American Delayed Price. Currency in USD
Add to watchlist
0.7250-0.0207 (-2.78%)
At close: 04:00PM EDT
0.7100 -0.02 (-2.07%)
Pre-Market: 08:18AM EDT
Full screen
Loading interactive chart...
  • GlobeNewswire

    AIM ImmunoTech Announces Commencement of Phase 2 Study of Ampligen® for the Treatment of Pancreatic Cancer

    Kazem Kazempour, Ph.D., President and CEO of Amarex Clinical Research, LLC Kazem Kazempour, Ph.D., President and CEO of Amarex Clinical Research, LLC Company receives IRB approval of study protocol Ampligen® (rintatolimod) has demonstrated promising activity as a potential maintenance therapy after systemic chemotherapy in patients with locally advanced pancreatic cancer OCALA, Fla., Aug. 18, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-ph

  • GlobeNewswire

    AIM Stockholder Full Value Committee Reiterates Intent to Proceed with Nominations and Proxy Solicitation

    Court Orders AIM Not to Hold Annual Meeting Prior to October 31, 2022 Delaware Court Preliminary Injunction Hearing Scheduled for October 5, 2022 NEW YORK, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Jonathan Jorgl, an AIM ImmunoTech Inc. (NYSE American: AIM), (“AIM”) stockholder, together with his nominees, Robert L. Chioini and Michael Rice (collectively, the “AIM Stockholder Full Value Committee” or the “ASFV Committee”), today reiterated their commitment to proceed with the solicitation of proxies for

  • Business Wire

    AIM ImmunoTech Provides Update on Jorgl Activist Group Litigation

    OCALA, Fla., August 15, 2022--AIM ImmunoTech Inc. (NYSE: American AIM) ("AIM" or the "Company"), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, today issued the following statement regarding the outcome of a hearing in the Delaware Court of Chancery concerning a motion for a temporary restraining order ("TRO") sought by activist shareholder Jonathan Jorgl: